九典制药
(300705)
| 流通市值：57.28亿 | | | 总市值：77.43亿 |
| 流通股本：3.70亿 | | | 总股本：5.00亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 696,028,386.21 | 2,930,677,498.58 | 2,145,889,147.01 | 1,366,190,189.06 |
| 营业收入 | 696,028,386.21 | 2,930,677,498.58 | 2,145,889,147.01 | 1,366,190,189.06 |
| 二、营业总成本 | 557,618,213.75 | 2,408,149,342.53 | 1,683,616,597.25 | 1,091,540,764.04 |
| 营业成本 | 183,926,631.68 | 784,397,754.77 | 563,073,361.04 | 366,951,223.6 |
| 税金及附加 | 8,468,848.36 | 33,241,429.7 | 25,161,702.71 | 15,720,249.13 |
| 销售费用 | 271,128,344.99 | 1,238,708,073.61 | 855,062,640.57 | 546,256,965.63 |
| 管理费用 | 28,564,970.59 | 92,286,390.25 | 61,321,830.35 | 40,892,659.13 |
| 研发费用 | 63,106,394.07 | 245,966,883.05 | 167,429,052.23 | 114,005,004.98 |
| 财务费用 | 2,423,024.06 | 13,548,811.15 | 11,568,010.35 | 7,714,661.57 |
| 其中:利息费用 | 3,210,529.72 | 18,633,745.21 | 15,516,276.94 | 10,407,459.56 |
| 其中:利息收入 | 734,413.7 | 5,447,937.63 | 4,281,217.93 | 2,946,832.17 |
| 加:公允价值变动收益 | 0 | 0 | 0 | 0 |
| 加:投资收益 | 170,709.78 | 3,111,376.25 | 2,541,117.47 | 1,508,211.42 |
| 净敞口套期收益 | 0 | 0 | 0 | 0 |
| 资产处置收益 | 0 | 0 | 0 | 0 |
| 资产减值损失(新) | -1,655,808.94 | -6,481,156.42 | -3,593,078.26 | -2,792,912.7 |
| 信用减值损失(新) | 1,339,396.23 | 3,456,649.29 | 4,851,799.29 | 7,128,294.73 |
| 其他收益 | 6,907,915.13 | 52,368,635.62 | 41,834,753.24 | 37,796,525.54 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 145,172,384.66 | 574,983,660.79 | 507,907,141.5 | 318,289,544.01 |
| 加:营业外收入 | 100,184.4 | 1,636,520.18 | 671,453.42 | 433,754.09 |
| 减:营业外支出 | 2,138,943.89 | 4,426,323.17 | 2,819,130.93 | 2,065,365.34 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 143,133,625.17 | 572,193,857.8 | 505,759,463.99 | 316,657,932.76 |
| 减:所得税费用 | 17,357,915.65 | 59,816,683.64 | 56,024,682.12 | 32,527,444.07 |
| 六、净利润 | 125,775,709.52 | 512,377,174.16 | 449,734,781.87 | 284,130,488.69 |
| 持续经营净利润 | 125,775,709.52 | 512,377,174.16 | 449,734,781.87 | 284,130,488.69 |
| 终止经营净利润 | 0 | 0 | 0 | 0 |
| 归属于母公司股东的净利润 | 125,775,709.52 | 512,377,174.16 | 449,734,781.87 | 284,130,488.69 |
| 少数股东损益 | 0 | 0 | 0 | 0 |
| (一)基本每股收益 | 0.25 | 1.05 | 0.93 | 0.59 |
| (二)稀释每股收益 | 0.25 | 1.04 | 0.92 | 0.59 |
| 八、其他综合收益 | 0 | 4,882,664.77 | 2,788,850 | 2,788,850 |
| 归属于母公司股东的其他综合收益 | 0 | 4,882,664.77 | 2,788,850 | 2,788,850 |
| 九、综合收益总额 | 125,775,709.52 | 517,259,838.93 | 452,523,631.87 | 286,919,338.69 |
| 归属于母公司股东的综合收益总额 | 125,775,709.52 | 517,259,838.93 | 452,523,631.87 | 286,919,338.69 |
| 归属于少数股东的综合收益总额 | - | - | 0 | 0 |
| 公告日期 | 2025-04-24 | 2025-04-24 | 2024-10-29 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |